adesso (ADN1) Q3 2024 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 TU earnings summary
14 Jan, 2026Executive summary
Achieved record sales of €961.3 million for the first nine months of 2024, up 15% year-over-year, driven by strong organic growth and a 14% increase in average headcount.
EBITDA rose 24% year-over-year to €66.5 million, with Q3 EBITDA margin reaching 11.8% and improved capacity utilization.
Net income for 9M 2024 reached €2.5 million, a turnaround from a loss in the prior year period.
The company is on track to meet its full-year 2024 guidance, supported by improved utilization and an additional working day in Q4.
Focus remains on profitability and cautious optimism for 2025 amid macroeconomic and political uncertainties.
Financial highlights
Sales revenues grew 15% year-over-year to €961.3 million for 9M 2024; Q3 sales were €330.2 million, up 15% from Q3 2023.
EBITDA margin improved to 6.9% for 9M 2024 (up from 6.4%); Q3 margin reached 11.8%.
Earnings per share for 9M 2024 were €0.16, compared to -€0.05 in 9M 2023; Q3 EPS was €1.67, up from €0.86.
Net working capital reduced by 15% year-over-year, and net debt improved to -€101.5 million.
Free cash flow for 9M 2024 was -€30.7 million, a 64% improvement year-over-year, with factoring increased to €60 million.
Outlook and guidance
Full-year sales target of over €1.25 billion is within reach, with EBITDA expected between €80–110 million and a 7% margin.
Guidance confirmed for 2024, with strong demand for digitalization and software engineering services.
Q4 2024 benefits from one additional working day and potential license income.
Cautious optimism for 2025, with ongoing monitoring of macroeconomic and political uncertainties.
Latest events from adesso
- Sales up 11% with margin pressure; H2 2025 expected to drive earnings recovery.ADN1
Q1 2025 TU3 Feb 2026 - Sales up 16% to €631.1m, but negative EPS and lower EBITDA guidance due to margin pressure.ADN1
H1 20241 Feb 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025 - 12% sales and 34% EBITDA growth in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 202518 Aug 2025 - 14% organic growth and margin gains set stage for further expansion in 2025.ADN1
H2 20245 Jun 2025